Skip to Content

GT Biopharma Inc GTBP

Morningstar Rating
$4.43 +0.06 (1.37%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GTBP is trading at a 67% discount.
Price
$4.39
Fair Value
$57.78
Uncertainty
Extreme
1-Star Price
$624.88
5-Star Price
$8.64
Economic Moat
Ddtyk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GTBP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$4.37
Day Range
$4.434.81
52-Week Range
$3.5218.00
Bid/Ask
$4.06 / $4.74
Market Cap
$6.12 Mil
Volume/Avg
10,831 / 14,168

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
2

Valuation

Metric
GTBP
Price/Earnings (Normalized)
Price/Book Value
0.60
Price/Sales
Price/Cash Flow
Price/Earnings
GTBP

Financial Strength

Metric
GTBP
Quick Ratio
3.15
Current Ratio
3.15
Interest Coverage
−48.59
Quick Ratio
GTBP

Profitability

Metric
GTBP
Return on Assets (Normalized)
−85.97%
Return on Equity (Normalized)
−126.80%
Return on Invested Capital (Normalized)
−129.44%
Return on Assets
GTBP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVrycshxfsDcrpp$570.1 Bil
VRTX
Vertex Pharmaceuticals IncPmyhfrnjQzgspk$107.8 Bil
REGN
Regeneron Pharmaceuticals IncGfxzxztwVvhyf$105.6 Bil
MRNA
Moderna IncCdxblxgrkPkcd$42.3 Bil
ARGX
argenx SE ADRBnbgpbkfNsvs$23.7 Bil
BNTX
BioNTech SE ADRPqbgzskZyjmy$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncRwzrpszrFyymg$19.4 Bil
BMRN
Biomarin Pharmaceutical IncVsjcbqxyrNsfzgh$16.7 Bil
RPRX
Royalty Pharma PLC Class ASmpbpffhfMmzrrv$13.6 Bil
INCY
Incyte CorpGfmrpsjJpwpctb$12.8 Bil

Sponsor Center